XENE (STOCKS)
Xenon Pharmaceuticals Inc
$52.400000
+0.300000 (+0.58%)
Prev close: $52.100000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Ian C. Mortimer
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $5,065.28M
- Employees
- 327
- P/E (TTM)
- -11.14
- P/B (TTM)
- 3.76
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $27.51M |
| Operating Expenses | $412.66M |
| Depreciation and Amortization | $2.47M |
| Research and Development | $328.25M |
| Other Operating Expenses | $83.22M |
| Operating Income/Loss | -$412.66M |
| Income/Loss From Continuing Operations After Tax | -$383.17M |
| Income/Loss From Continuing Operations Before Tax | -$385.15M |
| Income Tax Expense/Benefit | -$1.98M |
| Income Tax Expense/Benefit, Deferred | -$1.54M |
| Net Income/Loss | -$383.17M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$383.17M |
| Net Income/Loss Available To Common Stockholders, Basic | -$383.17M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$4.70 |
| Diluted Earnings Per Share | -$4.70 |
| Basic Average Shares | 245,837,914 |
| Diluted Average Shares | 245,837,914 |
| Assets | $1.39B |
| Current Assets | $1.11B |
| Noncurrent Assets | $280.18M |
| Fixed Assets | $8.29M |
| Non-current Prepaid Expenses | $8.31M |
| Other Non-current Assets | $263.58M |
| Liabilities | $48.99M |
| Current Liabilities | $39.82M |
| Wages | $7.63M |
| Other Current Liabilities | $32.18M |
| Noncurrent Liabilities | $9.18M |
| Equity | $1.34B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.34B |
| Liabilities And Equity | $1.39B |
| Net Cash Flow From Operating Activities | -$306.36M |
| Net Cash Flow From Operating Activities, Continuing | -$306.36M |
| Net Cash Flow From Investing Activities | -$223.79M |
| Net Cash Flow From Investing Activities, Continuing | -$223.79M |
| Net Cash Flow From Financing Activities | $958.98M |
| Net Cash Flow From Financing Activities, Continuing | $958.98M |
| Exchange Gains/Losses | $392.00K |
| Net Cash Flow | $429.21M |
| Net Cash Flow, Continuing | $428.82M |
| Comprehensive Income/Loss | -$383.54M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$383.54M |
| Other Comprehensive Income/Loss | -$375.00K |